SLU7 and breast cancer: Tumor antigens are essential for successful vaccine, which determine the specificity and strength of elicited adaptive immune response.[36] The antigens of existing cancer vaccine strategies mainly are already known or identified from the resected cancer samples, while neoantigens of the cancer occurs during cancer progression, and thus the vaccines have rare capacity to prevent the cancer progression.[37, 38] SRSF1 is a well characterized splicing factor that have been reported highly expressed in advanced breast cancer.